SRL
NVCR icon

Scientech Research LLC’s NovoCure NVCR Stock Holding History

Scientech Research LLC’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-37,647
Closed -$645K – 770
2024
Q2 		$645K Buy
+37,647
New +$662K 0.13% 270

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Scientech Research LLC's NVCR Position: Q3 2024 in Review

Scientech Research LLC sold out of NovoCure (NVCR) in Q3 2024, closing a stake of 37,647 shares — an estimated $645K sold.

Scientech Research LLC first reported a position in NVCR in Q2 2024 and held it in 1 quarter. The position peaked at $645K in Q2 2024. 224 funds tracked by Wall St. Rank hold NVCR as of Q3 2024.

  • Scientech Research LLC reported no remaining NovoCure position as of Q3 2024 after selling out during the quarter.
  • Scientech Research LLC sold 37,647 NovoCure shares in Q3 2024, an estimated $645K.
  • Scientech Research LLC first reported a position in NovoCure in Q2 2024 and held it in 1 quarter.
  • Scientech Research LLC's NovoCure position peaked at $645K in Q2 2024.
  • 224 funds tracked by Wall St. Rank held NovoCure as of Q3 2024.

Based on Scientech Research LLC's 13F filing for Q3 2024, filed 14 Nov 2024.